© 2018 Smart + Strong. All Rights Reserved. Terms of use and Your privacy. Smart + Strong® is a registered trademark of CDM Publishing, LLC.
This is according to a Phase IIb trial of the medication.
Thanks to direct-acting antiviral treatment of hepatitis C, survival rates of those with decompensated cirrhosis due to hep C are rising.
Non-alcoholic fatty liver disease can lead to cirrhosis and liver cancer.
Madrigal Pharmaceuticals is the latest company to enter into what’s becoming a crowded market.
For those with NAFLD and NASH, health care costs can more than double in just five years if screening is delayed.
The costs rise particularly steeply for those who quickly progress to end-stage liver disease.
A European liver transplant registry saw a decline in hep C as a cause of needing a transplant.
A look at some of the fatty liver-related research from the 2018 International Liver Congress
Analysts say the market will reach $35 billion in the next few years.
This finding is specific to those who do not have liver cancer.
Nonalcoholic fatty liver disease and Nonalcoholic steatohepatitis are conditions that develops in patients who are not alcoholic.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.
